ER1120

22/02/2017 WHO Classification: Towards Personalized Medicine in Haematology CityWest Hotel, Saggart (Dublin), Ireland 9-11 March, 2017 Chairs: Mario Cazzola (Pavia), Matteo G Della Porta (Milan), Torsten Haferlach (Munich), Eva Hellstrdm-Lindberg (Stockholm), Andreas Hochhaus (Jena) Thursday, March 9,2017 13:00-13:15 Welcome SESSION I Introduction to the training course Genomics of Haematological Malignancies for the Practicing Clinician Chair: Bob Lowenberg (Rotterdam) 13:15-13:40 13:40-13:45 ABCs of genomics Nick Cross (Salisbury) Discussion 13:45-14:10 14:10-14:15 Genomic applications in the clinic: are we ready? Andreas Hochhaus (Jena) Discussion 14:15-14:40 14:40-14:45 Next-generation sequencing data analysis: critical issues Torsten Haferlach (Munich) Discussion 14:45-15:15 Round table/general discussion The 2016 WHO Classification of Haematological Malignancies: what’s new? Chair: Mario Cazzola (Pavia) 15:15-15:40 15:40-15:45 Update of the WHO classification of myeloid malignancies Mario Cazzola (Pavia) Discussion 15:45-16:10 16:10-16:15 Update of the WHO classification of lymphoid malignancies Steven Swcrdlow (Pittsburgh) Discussion 16:15-16:45 Round table/general discussion 16:45-17:15 Coffee Break 1  SESSION II Biologically-Based Acute Myeloid Leukaemia (AML) Therapy Chair: Torsten Haferlach (Munich) 17:15-17:40 17:40-17:45 Translational implications of the medical genomics Torsten Haferlach (Munich) in AML Discussion 17:45-18:10 18:10-18:15 Genotype-tailored therapy of AML Hartmut Dohncr (Ulm) Discussion 18:15-18:40 18:40-18:45 Towards personalized medicine in AML Bob Ldwcnberg (Rotterdam) Discussion 18:45-19:10 19:10-19:15 Precision medicine in AML: hope, hype or both? Robert P. Gale (London) Discussion 19:15-19:30 Round table/general discussion 19:30 Poster Viewing and Get together SESSION III Molecular Haematology: the Paradigm of Myeloproliferative Neoplasms (MPN) Chair: Andreas Hochhaus (Jena) 08:45-09:10 09:10-09:15 The evolving genomic landscape of Philadelphia-negative Mario Cazzola (Pavia) classical MPN Discussion 09:15-09:40 09:40-09:45 Genotype-based clinical decision making in MPN Francesco Passamonti (Varese) Discussion 09:45-10:10 10:10-10:15 The future of JAK inhibition in MPN Alessandro Vannucchi (Florence) Discussion 10:15-10:45 Round table/general discussion 10:45-11:15 Coffee Break SESSION IV Modern Diagnostics Applied to the Evaluation of Minimal Residual Disease: the example of CML Chair: Nick Cross (Salisbury) 11:15-11:40 11:40-11:45 CML monitoring: why, which, where and when? Andreas Hochhaus (Jena) Discussion 11:45-12:10 12:10-12:15 Current status of standardization efforts for PCR in CML Nick Cross (Salisbury) Discussion 12:15-12:40 12:40-12:45 Clinical significance of NGS in second-line Simona Soverini (Bologna) treatment and beyond Discussion 12:45-13:15 Round table/general discussion 2  13:15-14:15 SESSION V Lunch Changing Paradigms in Acute Lymphocytic Leukaemia (ALL): from the genome to the patient Chair: Jacob Rowe (Jerusalem) 14:15-14:40 14:40-14:45 The genomic landscape of ALL Christine Harrison (Newcastle) Discussion 14:45-15:10 15:10-15:15 Targeting signaling pathways in ALL: new insights Charles Mullighan (Memphis) Discussion 15:15-15:40 15:40-15:45 Clinically defining and managing high-risk adult patients Jacob Rowe (Jerusalem) with ALL Discussion 15:45-16:15 Round table/general discussion 16:15-16:45 Coffee Break SESSION VI 16:45-17:10 17:10-17:15 The Dawn of the Molecular Era in Myelodysplastic Syndromes (MDS) and Myclodysplastic/Mycloprolifcrative Neoplasms (MDS/MPN) Chair: Eva llcllstrom-Lindbcrg (Stockholm) Integration of somatic mutations into classification and Luca Malcovati (Pavia) prognostic scores in MDS Discussion 17:40-17:45 Implications of patient genome on clinical decision making Michaela Fontenay (Paris) in MDS/MPN Discussion 17:45-18:10 18:10-18:15 Personalized transplantation procedures in myeloid malignancies Matteo Della Porta (Milan) Discussion 18:15-18:40 Treating anaemia according to patient genome Eva Hellstrom-Lindberg 18:40-18:45 Discussion 18:45-19:15 Round table/general discussion 20.00 Dinner 17:15-17:40 (Stockholm) Saturday, March 11,2017 08:45-09:45 Meet the Expert sessions "Choosing Wisely" - Distinction between Clinically Relevant Genomic Information which is Crucial for Decision Making vs. Academic Interest MPN - Andreas Hochhaus (Jena) AML - Robert P. Gale (London) MDS - Matteo Della Porta (Milan) CLL - Gianluca Gaidano (Novara) 3  SESSION VII Personalized Treatment Strategies in Lymphoprolifcrative Disorders Chair: Gianluca Gaidano (Novara) 09:45-10:10 Therapeutic targeting of biology in CLL: focus on signaling kinase Stephan Stilgenbauer (Ulm) and apoptosis modulation Discussion 10:10-10:15 10:15-10:40 Gianluca Gaidano (Novara) 10:40-10:45 Mutations in CLL and how they affect therapy choice (focus on NOTCH 1, SF3B1, and TP53) Discussion 10:45-11:10 11:10-11:15 Genomic stratification for the treatment of lymphomas Discussion Laura Pasqualucci (New York) 11:15-11:40 11:40-11:45 Hairy cell leukaemia: targeting mutant BRAF Discussion Brunangelo Falini (Perugia) 11:45-12:15 Round lable/general discussion 12:15-12:30 Closing Remarks MEETING CLOSURE 4